Zacks Investment Research downgraded shares of Adaptimmune Therapeutics PLC (NASDAQ:ADAP) from a buy rating to a hold rating in a research report released on Monday, July 17th.
According to Zacks, “Adaptimmune Therapeutics plc is a biopharmaceutical company. The Company is focused on cancer immunotherapy products based on T-cell receptor platform. Adaptimmune Therapeutics plc is based in Abingdon, United Kingdom. “
Other equities research analysts have also recently issued research reports about the company. BidaskClub upgraded Adaptimmune Therapeutics PLC from a sell rating to a hold rating in a report on Sunday, July 16th. Cowen and Company reiterated a buy rating on shares of Adaptimmune Therapeutics PLC in a report on Tuesday, June 6th. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and three have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of Hold and an average price target of $12.08.
Shares of Adaptimmune Therapeutics PLC (ADAP) traded up 0.98% on Monday, hitting $5.16. The company had a trading volume of 64,268 shares. Adaptimmune Therapeutics PLC has a 52 week low of $3.76 and a 52 week high of $8.36.
Adaptimmune Therapeutics PLC (NASDAQ:ADAP) last posted its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.24). Adaptimmune Therapeutics PLC had a negative return on equity of 38.73% and a negative net margin of 438.00%. The business had revenue of $3.52 million for the quarter, compared to analysts’ expectations of $5.43 million. On average, analysts expect that Adaptimmune Therapeutics PLC will post ($1.05) EPS for the current year.
TRADEMARK VIOLATION WARNING: This report was first posted by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this report on another publication, it was illegally copied and reposted in violation of international trademark and copyright law. The original version of this report can be read at https://stocknewstimes.com/2017/08/14/adaptimmune-therapeutics-plc-adap-stock-rating-lowered-by-zacks-investment-research-updated-updated-updated.html.
Hedge funds have recently made changes to their positions in the company. NEA Management Company LLC raised its stake in shares of Adaptimmune Therapeutics PLC by 21.7% in the first quarter. NEA Management Company LLC now owns 12,025,999 shares of the biotechnology company’s stock worth $66,263,000 after buying an additional 2,145,000 shares during the last quarter. Tekla Capital Management LLC raised its stake in shares of Adaptimmune Therapeutics PLC by 158.9% in the first quarter. Tekla Capital Management LLC now owns 1,466,368 shares of the biotechnology company’s stock worth $8,080,000 after buying an additional 900,000 shares during the last quarter. Baillie Gifford & Co. raised its stake in shares of Adaptimmune Therapeutics PLC by 43.7% in the second quarter. Baillie Gifford & Co. now owns 1,323,308 shares of the biotechnology company’s stock worth $5,941,000 after buying an additional 402,324 shares during the last quarter. AXA purchased a new stake in shares of Adaptimmune Therapeutics PLC during the first quarter valued at $4,959,000. Finally, Renaissance Technologies LLC raised its stake in shares of Adaptimmune Therapeutics PLC by 75.4% in the first quarter. Renaissance Technologies LLC now owns 780,800 shares of the biotechnology company’s stock valued at $4,302,000 after buying an additional 335,700 shares in the last quarter. 56.34% of the stock is currently owned by institutional investors and hedge funds.
About Adaptimmune Therapeutics PLC
Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR, and produce TCR therapeutic candidates for administration to patients.
Get a free copy of the Zacks research report on Adaptimmune Therapeutics PLC (ADAP)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Adaptimmune Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics PLC and related companies with MarketBeat.com's FREE daily email newsletter.
